Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab

Zhao,Haifeng; Zhang,Le; Guo,Shanqi; Yuan,Tian; Xia,Bing; Zhang,Lianyu; Zhang,Yizhuo

doi:10.3892/ol.2015.3038

Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab

Authors:
- Haifeng Zhao
- Le Zhang
- Shanqi Guo
- Tian Yuan
- Bing Xia
- Lianyu Zhang
- Yizhuo Zhang
View Affiliations

Affiliations: Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China, Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China
Published online on: March 13, 2015 https://doi.org/10.3892/ol.2015.3038
Pages: 2307-2312

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aims of the present study were to elucidate the transcript levels of DNA methyltransferase (DNMT)1, DNMT3a and DNMT3b by quantitative polymerase chain reaction in patients with primary gastrointestinal diffuse large B‑cell lymphoma (PGI‑DLBCL), and determine the association of their expression with the clinical parameters and prognostic values of the disease. The results revealed that the expression of DNMT1 in patients with PGI‑DLBCL was significantly higher than that in healthy controls (P=0.04), while the expression of DNMT3a and DNMT3b were significantly lower (P<0.001 and P=0.001, respectively). The increased expression of DNMT1 was significantly correlated with shorter overall survival and progression‑free survival rates (P=0.018 and P=0.008, respectively). The multivariate analysis demonstrated that the level of DNMT1 was an independent prognostic factor. In conclusion, DNMT1 was identified to be an independent prognostic factor for predicting the survival of patients with PGI‑DLBCL; this suggests that it could be used as a marker to indicate the prognosis of PGI‑DLBCL.

View Figures

View References

1	Wang T, Gui W and Shen Q: Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis. Med Oncol. 27:661–666. 2010. View Article : Google Scholar : PubMed/NCBI
2	Herrmann R, Panahon AM, Barcos MP, Walsh D and Stutzman L: Gastrointestinal involvement in non-Hodgkin's lymphoma. Cancer. 46:215–222. 1980. View Article : Google Scholar : PubMed/NCBI
3	van Krieken JH, Otter R, Hermans J, et al: Malignant lymphoma of the gastrointestinal tract and mesentery. A clinico-pathologic study of the significance of histologic classification. NHL Study Group of the Comprehensive Cancer Center West. Am J Pathol. 135:281–289. 1989.PubMed/NCBI
4	Chen F, Yang G and Xia B: Increased expression of the spindle checkpoint protein BubR1 is associated with high cell proliferation in primary gastrointestinal diffuse large B cell lymphoma. Cell Biochem Biophys. 66:747–752. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ding D, Pei W, Chen W, Zuo Y and Ren S: Analysis of clinical characteristics, diagnosis, treatment and prognosis of 46 patients with primary gastrointestinal non-Hodgkin lymphoma. Mol Clin Oncol. 2:259–264. 2014.PubMed/NCBI
6	Li X, Shen W, Cao J, et al: Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases. Ann Hematol. 91:1721–1729. 2012. View Article : Google Scholar : PubMed/NCBI
7	Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene. 20:3139–3155. 2001. View Article : Google Scholar : PubMed/NCBI
8	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
9	Fitzpatrick DR and Wilson CB: Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol. 109:37–45. 2003. View Article : Google Scholar : PubMed/NCBI
10	Fatemi M, Hermann A, Gowher H and Jeltsch A: Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem. 269:4981–4984. 2002. View Article : Google Scholar : PubMed/NCBI
11	Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT and Wang YC: Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer. 55:205–213. 2007. View Article : Google Scholar : PubMed/NCBI
12	Saito Y, Kanai Y, Nakagawa T, et al: Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer. 105:527–532. 2003. View Article : Google Scholar : PubMed/NCBI
13	Oue N, Kuraoka K, Kuniyasu H, et al: DNA methylation status of hMLH1, p16(INK4a), and CDH1 is not associated with mRNA expression levels of DNA methyltransferase and DNA demethylase in gastric carcinomas. Oncol Rep. 8:1085–1089. 2001.PubMed/NCBI
14	Girault I, Tozlu S, Lidereau R and Bieche I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res. 9:4415–4122. 2003.PubMed/NCBI
15	Xing J, Stewart DJ, Gu J, Lu C, Spitz MR and Wu X: Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer. 98:1716–1722. 2008. View Article : Google Scholar : PubMed/NCBI
16	Hayette S, Thomas X, Jallades L, et al: High DNA methyltransferase DNMT3B levels: poor prognostic marker in acute myeloid leukemia. PLoS One. 7:e515272012. View Article : Google Scholar : PubMed/NCBI
17	Bai X, Song Z, Fu Y, et al: Clinicopathological significance and prognostic value of DNA methyltransferase 1, 3a, and 3b expressions in sporadic epithelial ovarian cancer. PLoS One. 7:e400242012. View Article : Google Scholar : PubMed/NCBI
18	Shaknovich R and Melnick A: Epigenetics and B-cell lymphoma. Curr Opin Hematol. 18:293–299. 2011. View Article : Google Scholar : PubMed/NCBI
19	Taylor KH, Briley A, Wang Z, Cheng J, Shi H and Caldwell CW: Aberrant epigenetic gene regulation in lymphoid malignancies. Semin Hematol. 50:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
20	De S, Shaknovich R, Riester M, et al: Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 9:e10031372013. View Article : Google Scholar : PubMed/NCBI
21	Pike BL, Greiner TC, Wang X, et al: DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia. 22:1035–1043. 2008. View Article : Google Scholar : PubMed/NCBI
22	Asmar F, Punj V, Christensen J, et al: Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica. 98:1912–1920. 2013. View Article : Google Scholar : PubMed/NCBI
23	Tomonaga M.: Outline and direction of revised WHO classification of tumors of haematopoietic and lymphoid tissues. Rinsho Ketsueki. 50:1401–1406. 2009.(In Japanese). PubMed/NCBI
24	No authors listed: 5th International Conference on Malignant Lymphoma, Part 2. Proceedings. Lugano, Switzerland, June 9–12, 1993. Ann Oncol. 5 (Suppl 2):S1–S163. 1994.PubMed/NCBI
25	Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
26	Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 17:12441999.PubMed/NCBI
27	Fukushige S and Horii A: DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med. 229:173–185. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sincic N and Herceg Z: DNA methylation and cancer: ghosts and angels above the genes. Curr Opin Oncol. 23:69–76. 2011. View Article : Google Scholar : PubMed/NCBI
29	Mutze K, Langer R, Schumacher F, et al: DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur J Cancer. 47:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
30	Chen W, Gao N, Shen Y and Cen JN: Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol. 25:823–831. 2010. View Article : Google Scholar : PubMed/NCBI
31	Gao P, Yang X, Xue YW, Zhang XF, Wang Y, Liu WJ and Wu XJ: Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. Cancer. 115:3222–3232. 2009. View Article : Google Scholar : PubMed/NCBI
32	Xing J, Stewart DJ, Gu J, Lu C, Spitz MR and Wu X: Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer. 98:1716–1722. 2008. View Article : Google Scholar : PubMed/NCBI
33	Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J and Kim DH: Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary non-small cell lung cancer. Cancer. 107:1042–1049. 2006. View Article : Google Scholar : PubMed/NCBI
34	Vallbohmer D, Brabender J, Yang D, et al: DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer. 8:39–44. 2006. View Article : Google Scholar : PubMed/NCBI
35	Wang W, Gao J, Man XH, Li ZS and Gong YF: Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. Oncol Rep. 21:1439–1447. 2009.PubMed/NCBI
36	Kreth S, Thon N, Eigenbrod S, et al: O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One. 6:e171562011. View Article : Google Scholar : PubMed/NCBI
37	Amara K, Ziadi S, Hachana M, Soltani N, Korbi S and Trimeche M: DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci. 101:1722–1730. 2010. View Article : Google Scholar : PubMed/NCBI